Odonate Therapeutics (ODT) Earns Outperform Rating from Analysts at Cowen

Cowen started coverage on shares of Odonate Therapeutics (NASDAQ:ODT) in a research note released on Tuesday. The firm issued an outperform rating on the stock.

Separately, Jefferies Group began coverage on shares of Odonate Therapeutics in a research report on Tuesday. They set a buy rating and a $40.00 price objective for the company.

Shares of Odonate Therapeutics (NASDAQ:ODT) traded up $0.06 during trading on Tuesday, reaching $24.19. 54,800 shares of the company were exchanged, compared to its average volume of 58,400. Odonate Therapeutics has a one year low of $22.31 and a one year high of $25.36.

In other Odonate Therapeutics news, Director Boxer Capital, Llc bought 416,666 shares of the business’s stock in a transaction dated Wednesday, December 6th. The shares were acquired at an average cost of $24.00 per share, with a total value of $9,999,984.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kevin C. Tang bought 1,291,666 shares of the business’s stock in a transaction dated Thursday, December 7th. The stock was acquired at an average cost of $24.00 per share, for a total transaction of $30,999,984.00. The disclosure for this purchase can be found here. Insiders bought a total of 1,709,332 shares of company stock worth $41,023,268 over the last ninety days.

ILLEGAL ACTIVITY WARNING: This story was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://transcriptdaily.com/2018/01/05/odonate-therapeutics-odt-earns-outperform-rating-from-analysts-at-cowen.html.

About Odonate Therapeutics

Odonate Therapeutics, LLC is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply